High Flow Nasal Cannula for Endoscopic Ultrasound
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines whether high flow nasal cannula oxygen therapy is more effective than standard oxygen for individuals with a high BMI (body mass index of 35 or more) undergoing an endoscopic ultrasound. An endoscopic ultrasound uses a small camera to examine the digestive system. The study includes two groups: one receiving standard oxygen therapy and the other using the high flow nasal cannula. It seeks participants who are not on home oxygen therapy and are not undergoing complicated procedures, such as combined treatments. As an unphased trial, this study allows participants to contribute to important research that may enhance oxygen therapy options for individuals with a high BMI.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the high flow nasal cannula is safe for endoscopic ultrasound?
Research has shown that high flow nasal cannula (HFNC) oxygen therapy is generally safe. Studies have found that HFNC significantly reduces the risk of low oxygen levels during long endoscopic procedures, indicating it is well-tolerated by patients. Its common use in children with breathing problems further supports its safety. Although HFNC does not always eliminate the need for additional breathing support, it improves oxygen levels in many patients. Overall, HFNC is considered a safe method for providing oxygen during medical procedures.12345
Why are researchers excited about this trial?
Researchers are excited about the high flow nasal cannula (HFNC) for endoscopic ultrasound because it offers a new way to deliver oxygen more effectively. Unlike standard oxygen therapy, which typically uses 2-4 liters of oxygen through a regular nasal cannula, the HFNC delivers oxygen at much higher flow rates with 100% oxygen concentration. This method can improve oxygenation during procedures, potentially enhancing patient safety and comfort. By providing a more controlled and efficient oxygen delivery, HFNC may reduce complications and improve outcomes during endoscopic procedures.
What evidence suggests that high flow nasal cannula is effective for endoscopic ultrasound?
This trial will compare the effectiveness of High Flow Nasal Cannula (HFNC) oxygen therapy with standard oxygen therapy during endoscopic ultrasound procedures. Studies have shown that HFNC can reduce low blood oxygen levels during endoscopy procedures. Specifically, one study found that HFNC significantly lowered the number of low oxygen cases compared to standard oxygen therapy in patients undergoing long upper gastrointestinal procedures. Another study demonstrated that HFNC helps maintain better oxygen levels during endoscopy with sedation. Although some research suggests it is not always superior to traditional methods, HFNC has shown potential benefits, particularly for high-risk patients. This treatment may deliver oxygen more effectively than standard nasal cannulas.12346
Who Is on the Research Team?
Bhargavi Gali, MD, MHA
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for high-risk patients needing an endoscopy procedure. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and may be excluded based on factors like other medical conditions or treatments that could interfere with the study.Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either high flow nasal cannula or standard oxygen therapy during endoscopic ultrasound
Follow-up
Participants are monitored for recovery time and procedural conditions after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- High Flow Nasal Cannula
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Fisher and Paykel Healthcare
Industry Sponsor
Dr. Justin Vaughan
Fisher and Paykel Healthcare
Chief Medical Officer since 2024
MD from the University of Auckland
Lewis Gradon
Fisher and Paykel Healthcare
Chief Executive Officer since 2016
Bachelor of Science in Physics from the University of Auckland, New Zealand